The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparing the treatment outcomes between unresectable and recurrent cases receiving gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer: Pooled analysis of two prospective studies.
Takashi Sasaki
No relevant relationships to disclose
Hiroyuki Isayama
No relevant relationships to disclose
Yukiko Ito
No relevant relationships to disclose
Ichiro Yasuda
No relevant relationships to disclose
Nobuo Toda
No relevant relationships to disclose
Hiroshi Yagioka
No relevant relationships to disclose
Saburo Matsubara
No relevant relationships to disclose
Keiji Hanada
No relevant relationships to disclose
Hiroyuki Maguchi
No relevant relationships to disclose
Hideki Kamada
No relevant relationships to disclose
Osamu Hasebe
No relevant relationships to disclose
Tsuyoshi Mukai
No relevant relationships to disclose
Sumihiro Okabe
No relevant relationships to disclose
Iruru Maetani
No relevant relationships to disclose